Stockreport

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

OptiNose, Inc.  (OPTN) 
Last optinose, inc. earnings: 3/5 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.optinose.com
PDF ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients wi [Read more]